J&J analyst day tries to steer focus to drug business as talc baby powder comes under fire
CNBC - Wed 15 May 16:36 GMT

Johnson & Johnson's pharmaceutical business will take the spotlight Wednesday at the company's analyst day as the company shares its plans for the next few years and tries to allay investors' concerns over talc-based baby powder.

J&J analyst day tries to steer focus to drug business as talc baby powder comes under fire

  Johnson & Johnson's pharmaceutical business will take the spotlight Wednesday at its annual meeting with analysts as the company tries to allay investors' concerns over its talc-based baby powder.

  The New Brunswick, New Jersey, based health-care conglomerate makes a wide range of products, including everyday household products like Tylenol, Neutrogena face wash and Acuvue contacts as well as prescription drugs Xarelto and Invokana.

  Prescription drugs are the biggest revenue driver for J&J, accounting for half of its $81.58 billion in 2018 sales.

  But its consumer products division has come under pressure amid thousands of lawsuits that accuse its namesake talc baby powder of causing cancer.